Delving into the Latest Updates on IMU-201 with Synapse

Overview

Basic Info

Drug Type

Therapeutic vaccine

Synonyms

KEY-Vaxx, PD-1 (KEY-Vaxx), PD-1 VACCINE

+ [5]

Target

PD-1

Mechanism

PD-1 inhibitors(Programmed cell death protein 1 inhibitors)

Therapeutic Areas

NeoplasmsDigestive System DisordersRespiratory Diseases

Active Indication

Microsatellite instability-high colorectal cancerAdenocarcinoma of Lungmetastatic non-small cell lung cancer+ [3]

Inactive Indication-

Originator Organization

Imugene Ltd.

Active Organization

Imugene Ltd.

Inactive Organization-

Drug Highest PhasePhase 2

First Approval Date-

Regulation-

Login to view timeline

The aim of Neo-POLEM is to determine the rate of Major Pathological Response (MPR) of <10% viable tumour cells after administering neoadjuvant PD-1 vaccine IMU-201 (PD1-Vaxx), as measured by percentage change pre- and post-treatment in operable MSI high CRC patients.
All patients will be administered three doses of the PD1-Vaxx prior to resection surgery and will be followed up for a minimum of 2 years.

Start Date01 Dec 2024

Sponsor / Collaborator

The University of Southampton

ChiCTR2400082637

/ SuspendedNot ApplicableIIT

Study on the Differentiation Characteristics of Tumor-Specific Memory CD8 T Cells in Drainage Lymph Nodes and Their Response to PD-1 Immunotherapy Mechanism study

Start Date02 Apr 2024

Sponsor / Collaborator

Anhui Medical University No. 1 Affiliated Hospital

ChiCTR2300074577

/ RecruitingEarly Phase 1IIT

A single-center, single-arm, observational study of fruquinitinib combined with capecitabine and PD-1 in neoadjuvant therapy for colorectal cancer

Start Date11 Aug 2023

Sponsor / Collaborator

Shandong Provincial Hospital

100 Clinical Results associated with IMU-201

Login to view more data

100 Translational Medicine associated with IMU-201

Login to view more data

100 Patents (Medical) associated with IMU-201

Login to view more data

21

Literatures (Medical) associated with IMU-201

01 Feb 2025·Journal of Health Politics, Policy and Law

Political Partisanship, Confucian Collectivism, and Public Attitudes toward the Vaccination Policy in Taiwan

Article

Author: Yeh, Ming-Jui ; Hsieh, Yu-Chun

AbstractContext: Conventional wisdom suggests that people with a collectivist tradition tend to comply more with the government's regulatory and even coercive disease-prevention policies. In addition to this sociocultural element, political partisanship is also an important aspect relating to people's willingness to cooperate with the government. This study aims to examine the relationships between these two factors and three dimensions of vaccination policy attitudes: common responsibility to take the vaccine, the government's vaccine mandate, and indignation over anti-vaxxers.Methods: Using data from a nationally representative cross-sectional survey conducted in 2022 in Taiwan, this study applies multiple linear ordinary least squares regression to examine the relationships between vaccination policy attitudes and Confucian collectivism and political partisanship.Findings: Confucian collectivism and political partisanship aligning with the ruling party are associated with attitudes supporting vaccination policy. For those who do not align with the ruling party, negative attitudes toward the vaccination policy appear in different dimensions according to the party they lean toward.Conclusions: Confucian collectivism is prevalent in Taiwan and is related to public attitudes toward vaccination policy. This association is independent of political partisanship. Public health authorities should consider the sociocultural context and political atmosphere for the effectiveness of disease-prevention measures.

13 Sep 2024·Clinical Cancer Research

Phase II Trial of HER-Vaxx, a B-cell Peptide-Based Vaccine, in HER2-Overexpressing Advanced Gastric Cancer Patients Under Platinum-Based Chemotherapy (HERIZON)

Article

Author: Wiedermann, Ursula ; Chawla, Tanuj ; Chong, Leslie Mi Ok ; Nikolić, Ivan ; Petrović, Zoran ; Ryspayeva, Dinara ; Yavrom, Sharon ; Nixon, Bonnie ; Ede, Nicholas J. ; Kundi, Michael ; Andrić, Zoran ; Maglakelidze, Marina ; Bulat, Iurie ; Garner-Spitzer, Erika ; Zielinski, Christoph C. ; Nagarkar, Rajnish ; Tobias, Joshua

AbstractPurpose:A multicenter, randomized, open-label, phase II study (HERIZON; NCT02795988) was conducted to evaluate the clinical and immunologic efficacy of HER-Vaxx (IMU-131), a B-cell, peptide-based vaccine targeting HER2 overexpressed in 6% to 30% of gastroesophageal adenocarcinomas (GEA).Patients and Methods:Patients (n = 36) with GEA were treated with standard-of-care chemotherapy (n = 17) or HER-Vaxx plus chemotherapy (n = 19), using the recommended phase 2 dose for the vaccine. Overall survival (OS; primary endpoint), safety, progression-free survival (PFS), clinical response (secondary endpoints), and vaccine-induced HER2-specific antibody levels in serum and correlation with tumor response rates (exploratory endpoints) were investigated.Results:A 40% OS benefit [HR, 0.60; median OS, 13.9 months; 80% confidence interval (CI), 7.52–14.32] for patients treated with HER-Vaxx plus chemotherapy compared with OS of 8.31 months (80% CI, 6.01–9.59) in patients that received chemotherapy alone. A 20% PFS difference was obtained for the vaccination arm (HR, 0.80; 80% CI, 0.47, 1.38). No additional toxicity due to HER-Vaxx was observed. The vaccine-induced high levels of HER2-specific total IgG and IgG1 antibodies (P < 0.001 vs. controls) that significantly correlated with tumor reduction (IgG, P = 0.001; IgG1, P = 0.016), had a significant capacity in inhibiting phosphorylation of the intracellular HER2-signaling pathways, mediated antibody-dependent cellular cytotoxicity, and decreased immunosuppressive FOXP3+ regulatory T cells.Conclusions:HER-Vaxx plus standard chemotherapy exhibits an excellent safety profile and improves OS. Furthermore, vaccine-induced immune response was significantly associated with reduced tumor size compared with standard-of-care chemotherapy. The presented vaccination approach may substitute for treatment with trastuzumab, upon unavailability or toxicity, based on further evidence of equivalent treatment efficacy.

30 Dec 2023·Central European Journal of Public Health

The lingering challenge: addressing vaccine hesitancy in a post-pandemic world

Article

Author: Mir, Ethan Ayaan

Last time the world faced a deadly pandemic was the H1N1 Spanish flu in 1918, which affected almost one-third of the world's population (500 million people). Since then, almost 100 years later, we are now facing another pandemic of the SARS-CoV2 virus (COVID-19), which is still endemic to this day. As the technology evolved during those 100 years, an effective vaccine for COVID-19 was produced within only a year, a huge feat. But, unfortunately, due to its fast development, another force would arise limiting the impact of the vaccine: vaccine hesitancy and anti-vaxxers, which John Hopkins and the World Health Organization call the biggest current threat to global health. From politics to social media, it is clear that there has been a rapid spread of misinformation, resulting in hesitancy, especially from sociopolitically motivated people popularly referred to as anti-vaxxers. However, a second group of vaccine-hesitant people have also emerged, who are uneducated and remain undecided about vaccination mostly due to safety concerns. They come under the massive influence of anti-vaxxers and anti-vaccine propaganda through social media and politicians, which often make bold claims and huge headlines. To combat vaccine hesitancy, it is crucial that we debunk these conspiracy theories and misinformation that so many believe in, with factual, data-based information. Actively spreading correct information about the vaccines, such as disclosing the rigorous developmental processes and validation of safety data by the Food and Drug Administration (FDA), assurance for the unlikeliness of getting a lethal side effect along with tremendous health benefits, will encourage people for safe vaccination against COVID-19 and other potential infectious diseases in the future. This article discusses the role of anti-vaxxers and vaccine-hesitant groups, electronic social media, and politics in vaccine hesitancy among people. It describes the strategies to combat the roadblocks in the vaccination programmes and health benefits, offered by recent advances in scientific and technological developments.

100 Deals associated with IMU-201

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Microsatellite instability-high colorectal cancer	Phase 2	-	Imugene Ltd.	-
Adenocarcinoma of Lung	Phase 1	US	Imugene Ltd.	30 Nov 2020
Adenocarcinoma of Lung	Phase 1	AU	Imugene Ltd.	30 Nov 2020
metastatic non-small cell lung cancer	Phase 1	US	Imugene Ltd.	30 Nov 2020
metastatic non-small cell lung cancer	Phase 1	AU	Imugene Ltd.	30 Nov 2020
Non-small cell lung cancer stage IIIB	Phase 1	US	Imugene Ltd.	30 Nov 2020
Non-small cell lung cancer stage IIIB	Phase 1	AU	Imugene Ltd.	30 Nov 2020
Squamous non-small cell lung cancer	Phase 1	AU	Imugene Ltd.	30 Nov 2020
Squamous non-small cell lung cancer	Phase 1	US	Imugene Ltd.	30 Nov 2020
undifferentiated large cell lung cancer	Phase 1	US	Imugene Ltd.	30 Nov 2020

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ASCO2023	Not Applicable	Advanced Hepatocellular Carcinoma Second line	31	Regorafenib+PD-1+Local therapy	berlqkwjpc(nbhlpmijnq) = 47.1% (8/17) vs 35.7% (4/14), respectively nwwnppvity (utmhfasseh )	Positive	31 May 2023
				Regorafenib+PD-1
NCT04432207 (IMPRINTER, ASCO2022) Manual	Phase 1	Non-Small Cell Lung Cancer	4	imu-201 10 μg/dose	(xuyhxeaiza) = no observed zeriofrftn (jeuidrmnas )	Positive	02 Jun 2022
				imu-201 50 μg/dose